Globus Medical (GMED) Competitors

$89.97 -0.63 (-0.70%)

Closing price 03:59 PM Eastern

Extended Trading

$92.26 +2.29 (+2.54%)

As of 07:56 PM Eastern

GMED vs. EW, IDXX, BDX, RMD, and DXCM

Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Becton, Dickinson and Company (BDX), ResMed (RMD), and DexCom (DXCM). These companies are all part of the "health care equipment" industry.

How does Globus Medical compare to Edwards Lifesciences?

Edwards Lifesciences (NYSE:EW) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

: In the previous week, Edwards Lifesciences had 13 more articles in the media than Globus Medical. MarketBeat recorded 24 mentions for Edwards Lifesciences and 11 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.27 beat Edwards Lifesciences' score of 0.98 indicating that Globus Medical is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edwards Lifesciences
17 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Globus Medical
9 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Edwards Lifesciences has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
: 79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 0.3% of Edwards Lifesciences shares are owned by insiders. Comparatively, 18.4% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
: Edwards Lifesciences presently has a consensus price target of $95.65, indicating a potential upside of 15.31%. Globus Medical has a consensus price target of $104.36, indicating a potential upside of 16.00%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than Edwards Lifesciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences
0 Sell rating(s)
9 Hold rating(s)

16 Buy rating(s)

3 Strong Buy rating(s)
2.79
Globus Medical
0 Sell rating(s)

5 Hold rating(s)

8 Buy rating(s)

3 Strong Buy rating(s)
2.88
: Edwards Lifesciences has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Edwards Lifesciences $6.07B 7.88 $1.07B $1.88 44.12
Globus Medical $2.94B 4.14 $537.87M $3.94 22.84
: Globus Medical has a net margin of 18.30% compared to Edwards Lifesciences' net margin of 17.39%. Edwards Lifesciences' return on equity of 15.17% beat Globus Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
Edwards Lifesciences 17.39% 15.17% 11.68%
Globus Medical 18.30% 12.57% 10.87%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	17 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	2.88

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	7.88	$1.07B	$1.88	44.12
Globus Medical	$2.94B	4.14	$537.87M	$3.94	22.84

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.17%	11.68%
Globus Medical	18.30%	12.57%	10.87%

Summary

Edwards Lifesciences and Globus Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does Globus Medical compare to IDEXX Laboratories?

Globus Medical (NYSE:GMED) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

: In the previous week, IDEXX Laboratories had 14 more articles in the media than Globus Medical. MarketBeat recorded 25 mentions for IDEXX Laboratories and 11 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.27 beat IDEXX Laboratories' score of 1.08 indicating that Globus Medical is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Globus Medical
9 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEXX Laboratories
12 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Globus Medical has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, IDEXX Laboratories has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
: 95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Globus Medical presently has a consensus price target of $104.36, indicating a potential upside of 16.00%. IDEXX Laboratories has a consensus price target of $751.00, indicating a potential upside of 33.40%. Given IDEXX Laboratories' higher probable upside, analysts plainly believe IDEXX Laboratories is more favorable than Globus Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Globus Medical
0 Sell rating(s)
5 Hold rating(s)

8 Buy rating(s)

3 Strong Buy rating(s)
2.88
IDEXX Laboratories
0 Sell rating(s)

4 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.64
: IDEXX Laboratories has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Globus Medical $2.94B 4.14 $537.87M $3.94 22.84
IDEXX Laboratories $4.30B 10.39 $1.06B $13.07 43.07
: IDEXX Laboratories has a net margin of 24.62% compared to Globus Medical's net margin of 18.30%. IDEXX Laboratories' return on equity of 69.78% beat Globus Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
Globus Medical 18.30% 12.57% 10.87%
IDEXX Laboratories 24.62% 69.78% 31.91%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	12 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	2.88
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	4.14	$537.87M	$3.94	22.84
IDEXX Laboratories	$4.30B	10.39	$1.06B	$13.07	43.07

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.30%	12.57%	10.87%
IDEXX Laboratories	24.62%	69.78%	31.91%

Summary

IDEXX Laboratories beats Globus Medical on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to Becton, Dickinson and Company?

Globus Medical (NYSE:GMED) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

: Globus Medical presently has a consensus price target of $104.36, indicating a potential upside of 16.00%. Becton, Dickinson and Company has a consensus price target of $186.57, indicating a potential upside of 29.43%. Given Becton, Dickinson and Company's higher probable upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Globus Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Globus Medical
0 Sell rating(s)
5 Hold rating(s)

8 Buy rating(s)

3 Strong Buy rating(s)
2.88
Becton, Dickinson and Company
0 Sell rating(s)

9 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.44
: Globus Medical has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Becton, Dickinson and Company has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.
: 95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Becton, Dickinson and Company has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Globus Medical $2.94B 4.14 $537.87M $3.94 22.84
Becton, Dickinson and Company $21.84B 1.88 $1.68B $6.13 23.52
: Globus Medical has a net margin of 18.30% compared to Becton, Dickinson and Company's net margin of 8.01%. Becton, Dickinson and Company's return on equity of 15.76% beat Globus Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
Globus Medical 18.30% 12.57% 10.87%
Becton, Dickinson and Company 8.01% 15.76% 7.28%
: In the previous week, Becton, Dickinson and Company had 9 more articles in the media than Globus Medical. MarketBeat recorded 20 mentions for Becton, Dickinson and Company and 11 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.27 beat Becton, Dickinson and Company's score of 0.95 indicating that Globus Medical is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Globus Medical
9 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Becton, Dickinson and Company
10 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	2.88
Becton, Dickinson and Company	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	4.14	$537.87M	$3.94	22.84
Becton, Dickinson and Company	$21.84B	1.88	$1.68B	$6.13	23.52

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.30%	12.57%	10.87%
Becton, Dickinson and Company	8.01%	15.76%	7.28%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	10 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Globus Medical beats Becton, Dickinson and Company on 10 of the 17 factors compared between the two stocks.

How does Globus Medical compare to ResMed?

ResMed (NYSE:RMD) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

: ResMed has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
: ResMed currently has a consensus price target of $286.18, indicating a potential upside of 37.64%. Globus Medical has a consensus price target of $104.36, indicating a potential upside of 16.00%. Given ResMed's higher possible upside, equities analysts plainly believe ResMed is more favorable than Globus Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ResMed
0 Sell rating(s)
5 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.73
Globus Medical
0 Sell rating(s)

5 Hold rating(s)

8 Buy rating(s)

3 Strong Buy rating(s)
2.88
: ResMed has higher revenue and earnings than Globus Medical. ResMed is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ResMed $5.15B 5.89 $1.40B $10.37 20.05
Globus Medical $2.94B 4.14 $537.87M $3.94 22.84
: 55.0% of ResMed shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.7% of ResMed shares are held by company insiders. Comparatively, 18.4% of Globus Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: In the previous week, ResMed had 27 more articles in the media than Globus Medical. MarketBeat recorded 38 mentions for ResMed and 11 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.27 beat ResMed's score of 0.81 indicating that Globus Medical is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ResMed
15 Very Positive mention(s)
8 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Globus Medical
9 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: ResMed has a net margin of 27.44% compared to Globus Medical's net margin of 18.30%. ResMed's return on equity of 25.35% beat Globus Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
ResMed 27.44% 25.35% 18.69%
Globus Medical 18.30% 12.57% 10.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	2.88

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.89	$1.40B	$10.37	20.05
Globus Medical	$2.94B	4.14	$537.87M	$3.94	22.84

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	15 Very Positive mention(s)	8 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Globus Medical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Globus Medical	18.30%	12.57%	10.87%

Summary

ResMed beats Globus Medical on 10 of the 17 factors compared between the two stocks.

How does Globus Medical compare to DexCom?

DexCom (NASDAQ:DXCM) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

: DexCom has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
: DexCom currently has a consensus price target of $83.50, indicating a potential upside of 40.38%. Globus Medical has a consensus price target of $104.36, indicating a potential upside of 16.00%. Given DexCom's higher probable upside, equities research analysts plainly believe DexCom is more favorable than Globus Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom
1 Sell rating(s)
3 Hold rating(s)

18 Buy rating(s)

2 Strong Buy rating(s)
2.88
Globus Medical
0 Sell rating(s)

5 Hold rating(s)

8 Buy rating(s)

3 Strong Buy rating(s)
2.88
: DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DexCom $4.66B 4.92 $836.30M $2.34 25.42
Globus Medical $2.94B 4.14 $537.87M $3.94 22.84
: 97.8% of DexCom shares are owned by institutional investors. Comparatively, 95.2% of Globus Medical shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 18.4% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: In the previous week, DexCom had 31 more articles in the media than Globus Medical. MarketBeat recorded 42 mentions for DexCom and 11 mentions for Globus Medical. Globus Medical's average media sentiment score of 1.27 beat DexCom's score of 0.70 indicating that Globus Medical is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DexCom
18 Very Positive mention(s)
4 Positive mention(s)
14 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Globus Medical
9 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: DexCom has a net margin of 19.31% compared to Globus Medical's net margin of 18.30%. DexCom's return on equity of 33.33% beat Globus Medical's return on equity.
Company Net Margins Return on Equity Return on Assets
DexCom 19.31% 33.33% 13.19%
Globus Medical 18.30% 12.57% 10.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.88
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	2.88

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	4.92	$836.30M	$2.34	25.42
Globus Medical	$2.94B	4.14	$537.87M	$3.94	22.84

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	18 Very Positive mention(s)	4 Positive mention(s)	14 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Globus Medical	18.30%	12.57%	10.87%

Summary

DexCom beats Globus Medical on 12 of the 16 factors compared between the two stocks.

Get Globus Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMED vs. The Competition

Export

Metric	Globus Medical	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$12.25B	$7.14B	$6.24B	$22.94B
Dividend Yield	N/A	1.75%	2.73%	4.03%
P/E Ratio	22.84	29.60	29.04	28.60
Price / Sales	4.14	55.86	477.10	23.58
Price / Cash	14.42	24.91	27.62	19.03
Price / Book	2.66	7.18	9.67	4.68
Net Income	$537.87M	$158.34M	$3.55B	$1.07B
7 Day Performance	-0.77%	2.64%	1.70%	0.89%
1 Month Performance	2.56%	4.99%	5.62%	6.56%
1 Year Performance	27.63%	-3.14%	34.42%	31.66%

Globus Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMED Globus Medical	4.3984 of 5 stars	$89.97 -0.7%	$104.36 +16.0%	N/A	$12.25B	$2.94B	22.84	6,000	Positive News Upcoming Earnings
EW Edwards Lifesciences	4.1969 of 5 stars	$83.51 -0.8%	$95.65 +14.5%	N/A	$48.52B	$6.07B	45.63	16,000
IDXX IDEXX Laboratories	4.0185 of 5 stars	$574.95 +1.6%	$760.00 +32.2%	N/A	$44.95B	$4.30B	43.99	11,000	Trending News Earnings Report
BDX Becton, Dickinson and Company	4.9776 of 5 stars	$150.13 -1.3%	$189.08 +25.9%	N/A	$43.32B	$21.84B	24.49	72,000	Upcoming Earnings Dividend Announcement Analyst Forecast
RMD ResMed	4.8635 of 5 stars	$222.11 +1.0%	$294.55 +32.6%	N/A	$32.03B	$5.15B	21.97	10,600	Earnings Report Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GMED) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Competitors

GMED vs. EW, IDXX, BDX, RMD, and DXCM

How does Globus Medical compare to Edwards Lifesciences?

Summary

How does Globus Medical compare to IDEXX Laboratories?

Summary

How does Globus Medical compare to Becton, Dickinson and Company?

Summary

How does Globus Medical compare to ResMed?

Summary

How does Globus Medical compare to DexCom?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Competitors

GMED vs. EW, IDXX, BDX, RMD, and DXCM

How does Globus Medical compare to Edwards Lifesciences?

Summary

How does Globus Medical compare to IDEXX Laboratories?

Summary

How does Globus Medical compare to Becton, Dickinson and Company?

Summary

How does Globus Medical compare to ResMed?

Summary

How does Globus Medical compare to DexCom?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools